2011 Portfolio Company News

December 14, 2011

Anthera Announces Completion of Safety Review by DSMB for VISTA-16, Enrollment in VISTA-16 Continues Without Modification

December 8, 2011

SEQUEL Trial Results for VIVUS’ Qnexa Published in AJCN Show 10% Sustained Weight Loss Over 2 Years

December 1, 2011

Anthera Pharmaceuticals Completes Interim B-Cell Analysis of PEARL-SC Study, Reductions Consistent with Previous Clinical Studies with Blisibimod (A-623)

September 1, 2011

VIVUS Announces FDA Acceptance of Avanafil New Drug Application for Treatment of Erectile Dysfunction

May 10, 2011

Gentium Announces Submission of a Marketing Authorization Application for Defibrotide to the European Medicines Agency

April 18, 2011

Anthera Pharmaceuticals Successfully Competes Interim Biomarker Analysis of VISTA-16 Study and Third Safety Review of Varespladib Methyl

April 3, 2011

Regado Biosciences, Inc. Presents Results of the RADAR Phase 2b Clinical Trial of its REG1 Anticoagulation System

March 21, 2011

Cephalon Announces Definitive Agreement to Acquire Gemin X

RECENT VALENCE NEWS

June 2, 2020

CalciMedica Announces Robert N. Wilson Formerly of J&J as Co-Chairman of the Board of Directors and Eric Roberts as Vice Chairman

May 28, 2020

CalciMedica Announces Positive Topline Data from Interim Analysis of Trial Evaluating Auxora™ in Patients with Severe COVID-19 Pneumonia

May 22, 2020

CalciMedica Raises $15 Million in Series C Financing Round Led by Valence Life Sciences

May 21, 2020

CalciMedica Announces That FDA Has Strong Recommended Moving to a Blinded Placebo-Controlled Trial With Auxora in Patients With Severe COVID-19 Pneumonia

May 20, 2020

Atea Pharmaceuticals Announces IND Clearance of AT-527 for COVID-19 and $215 Million Financing

January 23, 2020

Leap Therapeutics Presents Updated Data at the ASCO 2020 Gastrointestinal Cancers Symposium (ASCO GI) Global Meeting

December 9, 2019

Merck to Acquire ArQule For $2.7 Billion

November 8, 2019

HCV Viral Kinetic Analysis Predicts Shorter Treatment duration with AT-527, a Purine Nucleotide Prodrug with Potent Pan-Genotypic Antiviral Activity in HCV-Infected Subjects Regardless of Cirrhosis Status